Adial shareholders approve authorized share increase, reverse split, and equity plan amendment at 2025 annual meeting

ADIAL PHARMACEUTICALS, INC.

Approved increase in authorized common stock from 50M to 100M shares, effective August 1, 2025.
Approved reverse stock split at a ratio of 1-for-2 to 1-for-25, with ratio set by Board.
Approved Amendment No. 7 to 2017 Equity Plan, increasing reserved shares from 2M to 5M.
Approved issuance of up to 6.73M shares upon exercise of Series B-1/C-1 warrants from May 2025 offering.
Approved issuance of up to 19.425M shares upon exercise of Series D/E warrants from June 2025 offering.

item 5.02item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.